<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01916109</url>
  </required_header>
  <id_info>
    <org_study_id>10-103</org_study_id>
    <nct_id>NCT01916109</nct_id>
  </id_info>
  <brief_title>Study of Gemcitabine, Carboplatin, and Panitumumab (GCaP) as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer</brief_title>
  <official_title>Phase II Study of Gemcitabine, Carboplatin, and Panitumumab (GCaP) as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to find out if using the combination of standard chemotherapy&#xD;
      (gemcitabine and carboplatin) plus this new drug (panitumumab) can help to shrink the tumor&#xD;
      before the patient undergoes surgery for bladder cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Lack of accrual&#xD;
  </why_stopped>
  <start_date>August 2013</start_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pathologic Complete Response Rate (&lt;pT0)</measure>
    <time_frame>1 year</time_frame>
    <description>The absence of carcinoma (pT0 disease) and the absence of microscopic lymph node metastases (N0) on the final cystectomy specimen.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Bladder Cancer</condition>
  <arm_group>
    <arm_group_label>Gemcitabine, Carboplatin, and Panitumumab (GCaP)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive four cycles of GCaP administered every 21 days. Panitumumab will be administered intravenously at a dose of 9mg/kg on day 1. Gemcitabine 1,000 mg/m2 on day 1 and 8 and carboplatin AUC 4.5 on day 1 will be administered intravenously on a 21-day cycle. A total of four cycles of therapy will be administered at 21-day intervals followed by radical cystectomy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <arm_group_label>Gemcitabine, Carboplatin, and Panitumumab (GCaP)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <arm_group_label>Gemcitabine, Carboplatin, and Panitumumab (GCaP)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Panitumumab</intervention_name>
    <arm_group_label>Gemcitabine, Carboplatin, and Panitumumab (GCaP)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>radical cystectomy</intervention_name>
    <arm_group_label>Gemcitabine, Carboplatin, and Panitumumab (GCaP)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed muscle invasive transitional cell carcinoma of the bladder at&#xD;
             MSKCC (Note: urothelial carcinoma invading into the prostatic stroma with no&#xD;
             histologic muscle invasion is allowed, provided the extent of disease is confirmed via&#xD;
             imaging and/or EUA.)&#xD;
&#xD;
          -  Clinical stage T2-T4a N0/X M0 disease.&#xD;
&#xD;
          -  Medically appropriate candidate for radical cystectomy as per MSKCC attending urologic&#xD;
             oncologist&#xD;
&#xD;
          -  Karnofsky Performance Status ≥ 80%&#xD;
&#xD;
          -  Age ≥ 18 years of age&#xD;
&#xD;
          -  Required Initial Laboratory Values:&#xD;
&#xD;
        Absolute neutrophil count ≥ 1500 cells/mm3&#xD;
&#xD;
          -  Platelets ≥ 100,000 cells/mm3&#xD;
&#xD;
          -  Hemoglobin ≥ 9.0g/dL&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 the upper limit of normal (ULN) for the institution&#xD;
&#xD;
          -  Aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 2.5 x ULN for the&#xD;
             institution&#xD;
&#xD;
          -  Alkaline phosphatase ≤ 2.5 x ULN for the institution&#xD;
&#xD;
          -  Serum magnesium &gt; 1.4 mEq/L&#xD;
&#xD;
          -  Serum creatinine ≤ 2.0 mg/dL&#xD;
&#xD;
          -  Cisplatin ineligibility based on one or more of the following criteria:&#xD;
&#xD;
        Estimated glomerular filtration rate (eGFR) 30-59 ml/min/1.73m2 using the CKD-EPI&#xD;
        equation:(http://nephron.org/MDRD_GFR.cgi) :&#xD;
&#xD;
        eGFR = 141 x min(Scr/k, 1)a x max(Scr/k, 1)-1.209 x 0.993Age x 1.018 [if female] x 1.159&#xD;
        [if black] Scr is serum creatinine, k is 0.7 for females and 0.9 for males, a is -0.329 for&#xD;
        females and -0.411 for males, min indicates the minimum of Scr/k or 1, and max indicates&#xD;
        the maximum of Scr/k or 1.&#xD;
&#xD;
          -  Grade 2 sensory neuropathy&#xD;
&#xD;
          -  Grade 2 hearing loss&#xD;
&#xD;
               -  Patients must provide a pretreatment saliva sample for genomic analysis.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior systemic chemotherapy (prior intravesical therapy is allowed)&#xD;
&#xD;
          -  Serious intercurrent medical or psychiatric illness.&#xD;
&#xD;
          -  Prior radiation therapy to the bladder.&#xD;
&#xD;
          -  Concomitant use of any other investigational drugs&#xD;
&#xD;
          -  Any of the following within the 6 months prior to study drug administration:&#xD;
             myocardial infarction, grade 2 or greater peripheral vascular disease, arterial&#xD;
             thrombotic event, visceral arterial ischemia, cerebrovascular ischemia, transient&#xD;
             ischemic attack, percutaneous transluminal angioplasty or stent, or unstable angina.&#xD;
&#xD;
        Symptomatic and/or serious uncontrolled arrhythmia&#xD;
&#xD;
          -  Symptomatic congestive heart failure (NYHA class III or IVI)&#xD;
&#xD;
          -  History of interstitial lung disease e.g. pneumonitis or pulmonary fibrosis or&#xD;
             evidence of interstitial lung disease on baseline chest CT scan.&#xD;
&#xD;
          -  History of any medical or psychiatric condition or laboratory abnormality that in the&#xD;
             opinion of the investigator may increase the risk associated with the study&#xD;
             participation or investigational product(s) administration or may interfere with the&#xD;
             interpretation of the results.&#xD;
&#xD;
          -  Major surgery requiring general anesthesia within 21 days or minor surgery within 14&#xD;
             days of study enrollment. Subjects must have recovered from surgery related&#xD;
             toxicities.&#xD;
&#xD;
          -  Pulmonary embolism, deep vein thrombosis, or other significant venous event ≤ 8 weeks&#xD;
             before enrollment&#xD;
&#xD;
          -  Known allergy or hypersensitivity to any component of the study treatment(s)&#xD;
&#xD;
          -  Active infection requiring systemic treatment or any uncontrolled infections ≤14 days&#xD;
             prior to enrollment.&#xD;
&#xD;
          -  Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome&#xD;
             (AIDS)-related illness.&#xD;
&#xD;
          -  Concurrent treatment on another clinical trial. Supportive care trials, surgical&#xD;
             clinical trials or non-treatment trials, e.g. QOL, are allowed.&#xD;
&#xD;
          -  Ongoing treatment with therapeutic doses of warfarin (low dose warfarin up to 2 mg po&#xD;
             daily for thromboembolic prophylaxis is allowed).&#xD;
&#xD;
          -  Pregnancy or breast-feeding. Patients must be surgically sterile or be postmenopausal,&#xD;
             or must agree to use effective contraception during the period of therapy and for two&#xD;
             (2) months following the last dose of panitumumab. The definition of effective&#xD;
             contraception will be based on the judgment of the principal investigator or a&#xD;
             designated associate. Male patients must be surgically sterile or agree to use&#xD;
             effective contraception.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dean Bajorin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memoral Sloan Kettering Cancer Center</name>
      <address>
        <city>Basking Ridge</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center @ Suffolk</name>
      <address>
        <city>Commack</city>
        <state>New York</state>
        <zip>11725</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering at Mercy Medical Center</name>
      <address>
        <city>Rockville Centre</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memoral Sloan Kettering Cancer Center@Phelps</name>
      <address>
        <city>Sleepy Hollow</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org/</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>January 2016</verification_date>
  <study_first_submitted>August 2, 2013</study_first_submitted>
  <study_first_submitted_qc>August 2, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 5, 2013</study_first_posted>
  <results_first_submitted>January 14, 2016</results_first_submitted>
  <results_first_submitted_qc>January 14, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 12, 2016</results_first_posted>
  <last_update_submitted>January 14, 2016</last_update_submitted>
  <last_update_submitted_qc>January 14, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Gemcitabine</keyword>
  <keyword>Carboplatin</keyword>
  <keyword>Panitumumab</keyword>
  <keyword>(GCaP)</keyword>
  <keyword>radical cystectomy</keyword>
  <keyword>10-103</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Panitumumab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Gemcitabine, Carboplatin, and Panitumumab (GCaP)</title>
          <description>Gemcitabine, Carboplatin, and Panitumumab (GCaP) as Neoadjuvant Chemotherapy in Patients with Muscle-Invasive Bladder Cancer</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Gemcitabine, Carboplatin, and Panitumumab (GCaP)</title>
          <description>Gemcitabine, Carboplatin, and Panitumumab (GCaP) as Neoadjuvant Chemotherapy in Patients with Muscle-Invasive Bladder Cancer</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pathologic Complete Response Rate (&lt;pT0)</title>
        <description>The absence of carcinoma (pT0 disease) and the absence of microscopic lymph node metastases (N0) on the final cystectomy specimen.</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Gemcitabine, Carboplatin, and Panitumumab (GCaP)</title>
            <description>Gemcitabine, Carboplatin, and Panitumumab (GCaP) as Neoadjuvant Chemotherapy in Patients with Muscle-Invasive Bladder Cancer</description>
          </group>
        </group_list>
        <measure>
          <title>Pathologic Complete Response Rate (&lt;pT0)</title>
          <description>The absence of carcinoma (pT0 disease) and the absence of microscopic lymph node metastases (N0) on the final cystectomy specimen.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Gemcitabine, Carboplatin, and Panitumumab (GCaP)</title>
          <description>Gemcitabine, Carboplatin, and Panitumumab (GCaP) as Neoadjuvant Chemotherapy in Patients with Muscle-Invasive Bladder Cancer</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTC-4.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Wound dehiscence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTC-4.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Hearing impaired</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash pustular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Dean Bajorin</name_or_title>
      <organization>Memorial Sloan Kettering Cancer Center</organization>
      <phone>646-422-4333</phone>
      <email>bajorind@mskcc.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

